Markman Maurie
Cancer Treatment Centers of America, Philadelphia, PA, USA Drexel University College of Medicine, Philadelphia, PA, USA
Womens Health (Lond). 2016 Jul;12(4):396-9. doi: 10.1177/1745505716655555.
A discussion of rational endpoints in clinical trials seeking regulatory approval for new anti-neoplastic agents involving the three major gynecologic malignancies, cancers of the ovary, cervix, and endometrial, is particularly interesting as (in the opinion of this commentator) the conclusion will be different in the individual cancers.
对于寻求监管批准用于治疗三大妇科恶性肿瘤（卵巢癌、宫颈癌和子宫内膜癌）的新型抗肿瘤药物的临床试验中的合理终点进行讨论，特别有意思，因为（在本评论员看来）每种癌症的结论会有所不同。
